Chimeron Bio is developing personalized gene therapies using self-amplifying RNAs (saRNA). saRNAs are a recent advancement in synthetic genomics that has the potential to transform RNA therapy. Chimeron has developed a novel nanoparticle technology called Chimera Encased saRNA (ChaESAR) that harnesses the properties of saRNAs and synthetic genomics to engineer novel RNA drugs. Chimeron’s ChaESAR platform leverages the chimera encased saRNA to achieve superior expression and broader dynamics range compared to current mRNA technologies. Chimeron’s current pipeline includes programs in oncology, liver and vaccines for infectious diseases.

Chimeron Bio

Short description:

Drug notes:

Long description:

Jobs: